Axon Enterprise (AXON) is back in the spotlight after disclosures that President Donald Trump bought US$1 million to US$5 million of stock shortly before ICE floated a US$220 million TASER 10 procurement request.

Axon Enterprise’s share price has swung sharply in recent weeks, with a 7 day share price return of 34.25% and a 90 day share price return of 44.63%, even as the 1 year total shareholder return is down 24.95%. Short term momentum looks strong, while longer term holders are still sitting on sizeable gains over three and five years.

If the Axon Enterprise headlines have you rethinking exposure to public safety and defense technology, it may be worth broadening your search through 52 AI infrastructure stocks

With Axon Enterprise trading at US$597.04 and sitting roughly 11% below the average analyst price target, yet flagged as expensive by some intrinsic value models, investors face a key question: is there still upside here, or is the market already pricing in future growth?

Most Popular Narrative: 1.6% Undervalued

At a last close of $597.04 versus a narrative fair value of $606.83, Axon Enterprise sits just below that reference point. This puts more focus on how the business mix is evolving rather than on a big valuation gap.

One company I find particularly interesting is Axon Enterprise. Many investors still associate the company primarily with TASER devices, but I think the more compelling part of the story is how Axon has quietly transformed itself into a software and data platform for public safety. What began as a hardware business is increasingly becoming an ecosystem built around digital evidence, cloud software, and connected policing tools.

Want to see what this ecosystem focus means for Axon Enterprise's future numbers? The narrative leans heavily on recurring software revenue, expanding margins and a richer profit profile. Curious how those inputs combine to support the fair value estimate and growth outlook? The full narrative breaks down the assumptions that sit behind that price tag.

Result: Fair Value of $606.83 (UNDERVALUED)

However, Axon Enterprise’s story could be tested if public sector budgets tighten or if competing public safety platforms tempt agencies to reconsider long term contracts.

Another View on Axon Enterprise: Rich Sales Multiple, Limited Cushion

While the narrative fair value suggests Axon Enterprise is 1.6% undervalued, the P/S ratio tells a tougher story. At 16.1x sales versus 9.2x for peers and 5.7x for the wider US Aerospace & Defense industry, investors are already paying a premium with less room for mistakes.

Even against a fair ratio of 17.1x, the current 16.1x leaves only a narrow margin before Axon Enterprise would look stretched. This raises the question of whether future execution will justify sitting this far above peers or if the stock could drift closer to their multiples instead.

Next Steps

Sentiment on Axon Enterprise is clearly mixed. If this has your attention, take a closer look at the underlying data and form your own view while the story is evolving, starting with the 1 key reward and 3 important warning signs

Looking for more investment ideas beyond Axon Enterprise?

If Axon Enterprise has sharpened your focus on opportunities, do not stop here. Use the screeners below to quickly surface other stocks that might fit your style.

• Target potential mispricings by running a focused search through 43 high quality undervalued stocks and see which stocks currently sit out of favor with the market.
• Strengthen your portfolio foundations by filtering for companies in the solid balance sheet and fundamentals stocks screener (46 results) that pair financial resilience with underlying business quality.
• Spot potential future leaders early by scanning the screener containing 18 high quality undiscovered gems before they attract wider attention and capital.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.